全球標靶治療市場研究報告 - 2024 年至 2032 年行業分析、規模、佔有率、成長、趨勢和預測

全球標靶治療市場需求預計將從 2023 年的 705.8 億美元達到近 1,343 億美元的市場規模，2024-2032 年研究期間CAGR為 7.41%。

標靶治療是一類選擇性針對疾病過程中涉及的特定分子或途徑的醫學治療。與傳統的廣譜療法不同，標靶療法旨在提供精確有效的治療，同時最大限度地減少對健康組織的不利影響。這些療法通常利用單株抗體、小分子抑制劑、基因療法或免疫療法來干擾癌細胞生長、抑制異常訊號傳導路徑或調節免疫系統的反應。

市場動態

分子生物學和基因組學的進步使人們能夠在分子層面上更深入地理解疾病機制，為開發能夠精確靶向致病分子、最大限度地減少副作用和提高療效的標靶療法鋪平了道路。此外，癌症、自體免疫疾病和心血管疾病等慢性疾病的發病率不斷增加，增加了對更有效和個人化治療方案的需求，進一步推動了標靶治療市場的發展。此外，旨在加快標靶藥物核准流程和製藥公司增加研發投資的監管措施也促進了市場成長。此外，擴大採用伴隨診斷來確定最有可能從標靶治療中獲益的個體，這正在提高市場滲透率。最後，次世代定序和基因編輯技術等技術進步為開發新型標靶療法、促進創新和推動市場擴張開闢了新途徑。然而，藥物開發的監管挑戰、高昂的研發成本以及來自既定治療方式的競爭可能會限制標靶治療市場。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球標靶治療市場的每個細分市場進行了包容性評估。標靶治療產業的成長和趨勢為這項研究提供了整體方法。

市場區隔

標靶治療市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按類型

• 單株抗體（血管新生抑制劑、Her-2 標靶藥物和抗 Cd20 單株抗體）
• 小分子（酪胺酸激酶抑制劑）

按申請

• 乳癌
• 大腸直腸癌
• 白血病
• 肺癌
• 淋巴瘤
• 多發性硬化症
• 腎癌
• 濕性老年黃斑部病變
• 其他（卵巢癌、輸卵管癌、前列腺癌和胰腺癌）

按配銷通路

• 醫院藥房
• 零售藥局
• 網路藥局

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲標靶治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。標靶治療市場的主要參與者包括賽諾菲、葛蘭素史克、武田藥品工業株式會社、默克公司、諾華公司、輝瑞公司、羅氏公司、阿斯特捷利康、Seagen公司.、拜耳公司、安進公司、百時美施貴寶公司。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章：前言

• 報告說明
  • 客觀的
  • 目標受眾
  • 獨特的銷售主張 (USP) 和產品
• 研究範圍
• 研究方法論
  • 市場研究過程
  • 市場研究方法論

第 2 章：執行摘要

• 市場亮點
• 全球市場概況

第 3 章：標靶治療 - 產業分析

• 簡介 - 市場動態
• 市場促進因素
• 市場限制
• 機會
• 產業動態
• 波特五力分析
• 市場吸引力分析
  • 按類型分類的市場吸引力分析
  • 市場吸引力分析：依應用分類
  • 按配銷通路分類的市場吸引力分析
  • 市場吸引力分析：按地區

第 4 章：價值鏈分析

• 價值鏈分析
• 原料分析
  • 原料清單
  • 原料廠商清單
  • 主要原物料價格走勢
• 潛在買家名單
• 行銷管道
  • 直效行銷
  • 間接行銷
  • 行銷通路發展趨勢

第 5 章：全球標靶治療市場分析：按類型

• 按類型概述
• 歷史和預測數據
• 按類型分析
• 單株抗體（血管新生抑制劑、HER-2標靶藥物和抗CD20單株抗體）
• 小分子（酪胺酸激酶抑制劑）

第 6 章：全球標靶治療市場分析：按應用分類

• 概述：按應用
• 歷史和預測數據
• 分析：按應用
• 乳癌
• 大腸直腸癌
• 白血病
• 肺癌
• 淋巴瘤
• 多發性硬化症
• 腎癌
• 濕性老年黃斑部病變
• 其他（卵巢癌、輸卵管癌、攝護腺癌、胰臟癌）

第 7 章：全球標靶治療市場分析：按分銷管道

• 按配銷通路分類的概覽
• 歷史和預測數據
• 按配銷通路分析
• 醫院藥房
• 零售藥局
• 網路藥局

第 8 章：全球標靶治療市場分析：按地理位置

• 區域展望
• 介紹
• 北美銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 北美按細分市場銷售分析
  • 北美按國家銷售分析
  • 美國銷售分析
  • 加拿大銷售分析
  • 墨西哥銷售分析
• 歐洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 歐洲按細分市場銷售分析
  • 歐洲按國家銷售分析
  • 英國銷售分析
  • 法國銷售分析
  • 德國銷售分析
  • 義大利銷售分析
  • 俄羅斯銷售分析
  • 歐洲其他地區銷售分析
• 亞太地區銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 亞太地區按細分市場銷售分析
  • 亞太地區國家/地區銷售分析
  • 中國銷售分析
  • 印度銷售分析
  • 日本銷售分析
  • 韓國銷售分析
  • 澳洲銷售分析
  • 東南亞銷售分析
  • 亞太地區其他地區銷售分析
• 拉丁美洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 拉丁美洲按細分市場銷售分析
  • 拉丁美洲按國家銷售分析
  • 巴西銷售分析
  • 阿根廷銷售分析
  • 秘魯銷售分析
  • 智利銷售分析
  • 拉丁美洲其他地區銷售分析
• 中東和非洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 中東和非洲按細分市場銷售分析
  • 中東和非洲國家銷售分析
  • 沙烏地阿拉伯銷售分析
  • 阿拉伯聯合大公國銷售分析
  • 以色列銷售分析
  • 南非銷售分析
  • 中東其他地區和非洲銷售分析

第 9 章：標靶治療公司的競爭格局

• 標靶治療市場競爭
• 夥伴關係/協作/協議
• 併購
• 新產品發布
• 其他發展

第 10 章：公司簡介

• 公司股份分析
• 市場集中度
• Sanofi
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• GlaxoSmithKline plc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Takeda Pharmaceutical Company Ltd.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Merck & Co. Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Novartis AG
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Pfizer Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• F. Hoffmann-La Roche Ltd.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• AstraZeneca
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Seagen Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Bayer AG
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Amgen Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Bristol-Myers Squibb Company
• 公司簡介
• 公司收入
• 產品
• 最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

The global demand for Targeted Therapeutics Market is presumed to reach the market size of nearly USD 134.3 Billion by 2032 from USD 70.58 Billion in 2023 with a CAGR of 7.41% under the study period 2024 - 2032.

Targeted therapeutics is a class of medical treatments that selectively target specific molecules or pathways involved in disease processes. Unlike traditional broad-spectrum therapies, targeted therapeutics aim to deliver precise and effective treatment while minimizing adverse effects on healthy tissues. These therapies often utilize monoclonal antibodies, small molecule inhibitors, gene therapies, or immunotherapies to interfere with cancer cell growth, inhibit abnormal signaling pathways, or modulate the immune system's response.

MARKET DYNAMICS

Progress in molecular biology & genomics has allowed for a more profound comprehension of disease mechanisms at the molecular level, paving the way for developing targeted therapies that can precisely target disease-causing molecules, minimizing side effects and improving efficacy. Additionally, the increasing incidence of chronic diseases such as cancer, autoimmune disorders, and cardiovascular diseases has increased the demand for more effective and personalized treatment options, further driving the market for targeted therapeutics. Moreover, regulatory initiatives aimed at expediting the approval process for targeted drugs and increasing investments in research and development by pharmaceutical companies are contributing to the market growth. Furthermore, the rising adoption of companion diagnostics to pinpoint individuals most likely to gain from targeted therapies is enhancing market penetration. Lastly, technological advancements such as next-generation sequencing and gene editing technologies open new avenues for developing novel targeted therapeutics, fostering innovation and driving market expansion. However, regulatory challenges in drug development, high research & development costs, and competition from established treatment modalities may restrict the targeted therapeutics Market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of targeted therapeutics. The growth and trends of targeted therapeutics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the targeted therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

• Monoclonal Antibodies (Angiogenesis Inhibitors, Her-2 Targeted Agents, And Anti-Cd20 Monoclonal Antibodies)
• Small Molecule (Tyrosine Kinase Inhibitors)

By Application

• Breast Cancer
• Colorectal Cancer
• Leukemia
• Lung Cancer
• Lymphoma
• Multiple Sclerosis
• Renal Cancer
• Wet Age-Related Macular Degeneration
• Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, And Pancreatic Cancer)

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Targeted Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Targeted Therapeutics market include Sanofi, GlaxoSmithKline plc., Takeda Pharmaceutical Company Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Seagen, Inc., Bayer AG, Amgen, Inc., Bristol-Myers Squibb Company. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . TARGETED THERAPEUTICS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Type
  • 3.7.2 Market Attractiveness Analysis By Application
  • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL TARGETED THERAPEUTICS MARKET ANALYSIS BY TYPE

• 5.1 Overview by Type
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Type
• 5.4 Monoclonal Antibodies (Angiogenesis Inhibitors, HER-2 Targeted Agents, and Anti-CD20 Monoclonal Antibodies) Historic and Forecast Sales by Regions
• 5.5 Small Molecule (Tyrosine Kinase Inhibitors) Historic and Forecast Sales by Regions

6 . GLOBAL TARGETED THERAPEUTICS MARKET ANALYSIS BY APPLICATION

• 6.1 Overview by Application
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Application
• 6.4 Breast Cancer Historic and Forecast Sales by Regions
• 6.5 Colorectal Cancer Historic and Forecast Sales by Regions
• 6.6 Leukemia Historic and Forecast Sales by Regions
• 6.7 Lung Cancer Historic and Forecast Sales by Regions
• 6.8 Lymphoma Historic and Forecast Sales by Regions
• 6.9 Multiple Sclerosis Historic and Forecast Sales by Regions
• 6.10. Renal Cancer Historic and Forecast Sales by Regions
• 6.11 Wet Age-related Macular Degeneration Historic and Forecast Sales by Regions
• 6.12 Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer) Historic and Forecast Sales by Regions

7 . GLOBAL TARGETED THERAPEUTICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 7.1 Overview by Distribution Channel
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Distribution Channel
• 7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
• 7.5 Retail Pharmacies Historic and Forecast Sales by Regions
• 7.6 Online Pharmacies Historic and Forecast Sales by Regions

8 . GLOBAL TARGETED THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2. North America By Segment Sales Analysis
  • 8.3.3. North America By Country Sales Analysis
  • 8.3.4. United State Sales Analysis
  • 8.3.5. Canada Sales Analysis
  • 8.3.6. Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2. Europe by Segment Sales Analysis
  • 8.4.3. Europe by Country Sales Analysis
  • 8.4.4. United Kingdom Sales Analysis
  • 8.4.5. France Sales Analysis
  • 8.4.6. Germany Sales Analysis
  • 8.4.7. Italy Sales Analysis
  • 8.4.8. Russia Sales Analysis
  • 8.4.9. Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2. Asia Pacific by Segment Sales Analysis
  • 8.5.3. Asia Pacific by Country Sales Analysis
  • 8.5.4. China Sales Analysis
  • 8.5.5. India Sales Analysis
  • 8.5.6. Japan Sales Analysis
  • 8.5.7. South Korea Sales Analysis
  • 8.5.8. Australia Sales Analysis
  • 8.5.9. South East Asia Sales Analysis
  • 8.5.10. Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2. Latin America by Segment Sales Analysis
  • 8.6.3. Latin America by Country Sales Analysis
  • 8.6.4. Brazil Sales Analysis
  • 8.6.5. Argentina Sales Analysis
  • 8.6.6. Peru Sales Analysis
  • 8.6.7. Chile Sales Analysis
  • 8.6.8. Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2. Middle East & Africa by Segment Sales Analysis
  • 8.7.3. Middle East & Africa by Country Sales Analysis
  • 8.7.4. Saudi Arabia Sales Analysis
  • 8.7.5. UAE Sales Analysis
  • 8.7.6. Israel Sales Analysis
  • 8.7.7. South Africa Sales Analysis
  • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE TARGETED THERAPEUTICS COMPANIES

• 9.1. Targeted Therapeutics Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10 . COMPANY PROFILES OF TARGETED THERAPEUTICS INDUSTRY

• 10.1. Company Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Sanofi
  • 10.3.1. Company Overview
  • 10.3.2. Company Revenue
  • 10.3.3. Products
  • 10.3.4. Recent Developments
• 10.4. GlaxoSmithKline plc.
  • 10.4.1. Company Overview
  • 10.4.2. Company Revenue
  • 10.4.3. Products
  • 10.4.4. Recent Developments
• 10.5. Takeda Pharmaceutical Company Ltd.
  • 10.5.1. Company Overview
  • 10.5.2. Company Revenue
  • 10.5.3. Products
  • 10.5.4. Recent Developments
• 10.6. Merck & Co. Inc.
  • 10.6.1. Company Overview
  • 10.6.2. Company Revenue
  • 10.6.3. Products
  • 10.6.4. Recent Developments
• 10.7. Novartis AG
  • 10.7.1. Company Overview
  • 10.7.2. Company Revenue
  • 10.7.3. Products
  • 10.7.4. Recent Developments
• 10.8. Pfizer Inc.
  • 10.8.1. Company Overview
  • 10.8.2. Company Revenue
  • 10.8.3. Products
  • 10.8.4. Recent Developments
• 10.9. F. Hoffmann-La Roche Ltd.
  • 10.9.1. Company Overview
  • 10.9.2. Company Revenue
  • 10.9.3. Products
  • 10.9.4. Recent Developments
• 10.10. AstraZeneca
  • 10.10.1. Company Overview
  • 10.10.2. Company Revenue
  • 10.10.3. Products
  • 10.10.4. Recent Developments
• 10.11. Seagen Inc.
  • 10.11.1. Company Overview
  • 10.11.2. Company Revenue
  • 10.11.3. Products
  • 10.11.4. Recent Developments
• 10.12. Bayer AG
  • 10.12.1. Company Overview
  • 10.12.2. Company Revenue
  • 10.12.3. Products
  • 10.12.4. Recent Developments
• 10.13. Amgen Inc.
  • 10.13.1. Company Overview
  • 10.13.2. Company Revenue
  • 10.13.3. Products
  • 10.13.4. Recent Developments
• 10.14. Bristol-Myers Squibb Company
  • 10.14.1. Company Overview
  • 10.14.2. Company Revenue
  • 10.14.3. Products
  • 10.14.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Type (USD MN)
• Monoclonal Antibodies (Angiogenesis Inhibitors, HER-2 Targeted Agents, and Anti-CD20 Monoclonal Antibodies) Market Sales by Geography (USD MN)
• Small Molecule (Tyrosine Kinase Inhibitors) Market Sales by Geography (USD MN)
• Analysis Market by Application (USD MN)
• Breast Cancer Market Sales by Geography (USD MN)
• Colorectal Cancer Market Sales by Geography (USD MN)
• Leukemia Market Sales by Geography (USD MN)
• Lung Cancer Market Sales by Geography (USD MN)
• Lymphoma Market Sales by Geography (USD MN)
• Multiple Sclerosis Market Sales by Geography (USD MN)
• Renal Cancer Market Sales by Geography (USD MN)
• Wet Age-related Macular Degeneration Market Sales by Geography (USD MN)
• Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer) Market Sales by Geography (USD MN)
• Analysis by Distribution Channel (USD MN)
• Hospital Pharmacies Market Sales by Geography (USD MN)
• Retail Pharmacies Market Sales by Geography (USD MN)
• Online Pharmacies Market Sales by Geography (USD MN)
• Global Targeted Therapeutics Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Targeted Therapeutics Report
• Market Research Process
• Market Research Methodology
• Global Targeted Therapeutics Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Type
• Market Attractiveness Analysis by Application
• Market Attractiveness Analysis by Distribution Channel
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Type (USD MN)
• Monoclonal Antibodies (Angiogenesis Inhibitors, HER-2 Targeted Agents, and Anti-CD20 Monoclonal Antibodies) Market Sales by Geography (USD MN)
• Small Molecule (Tyrosine Kinase Inhibitors) Market Sales by Geography (USD MN)
• Global Market Analysis by Application (USD MN)
• Breast Cancer Market Sales by Geography (USD MN)
• Colorectal Cancer Market Sales by Geography (USD MN)
• Leukemia Market Sales by Geography (USD MN)
• Lung Cancer Market Sales by Geography (USD MN)
• Lymphoma Market Sales by Geography (USD MN)
• Multiple Sclerosis Market Sales by Geography (USD MN)
• Renal Cancer Market Sales by Geography (USD MN)
• Wet Age-related Macular Degeneration Market Sales by Geography (USD MN)
• Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer) Market Sales by Geography (USD MN)
• Global Market Analysis by Distribution Channel (USD MN)
• Hospital Pharmacies Market Sales by Geography (USD MN)
• Retail Pharmacies Market Sales by Geography (USD MN)
• Online Pharmacies Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.